Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379328186> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4379328186 endingPage "e12617" @default.
- W4379328186 startingPage "e12617" @default.
- W4379328186 abstract "e12617 Background: Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates and moderate objective response rate (ORR) in hormone receptor (HR)-positive, HER2-negative breast cancer, more promising alternatives are urgently needed. Tucidinostat is an oral subtype-selective histone deacetylase inhibitor that has shown efficacy and safety when used in combination with exemestane in patients with advanced HR+ breast cancer. This MUKDEN 05 study aimed to assess the efficacy and toxicity of the combination of tucidinostat and EC-T as a neoadjuvant strategy in patients with HR+/HER2-, stage II-III breast cancer. Methods: This study is a multicenter, single-arm, phase II study. Eligible patients received 20 mg tucidinostat orally twice a week (on days 1, 4, 8, and 11), 2 weeks on, 1 week off. The dose and administration schedule of EC-T were as follows: 4 cycles of epirubicin 90 mg/m 2 and cyclophosphamide 600 mg/m 2 every 3 weeks, followed by 4 cycles of docetaxel 100 mg/m 2 every 3 weeks. The primary endpoint was the proportion of residual cancer burden (RCB) 0-I. Key secondary endpoints included pathological complete response (pCR), objective response rate (ORR), and safety. Results: Between May 2022 and August 2022, a total of 35 patients were enrolled. 27 patients were pathologically evaluable. The remaining 8 patients have completed neoadjuvant treatment and wait for operation. The ratio of RCB 0-I was 37% (95% CI, 23.2-53.7%). ORR was 86% (95% CI, 70.6-93.7%). Four (15%; 95% CI, 5.91-32.5%) patients achieved bpCR, and one (4%; 95% CI, 0.67-18.3%) patients achieved tpCR. Most adverse events (AEs) were grade 1 or 2. Grade 3/4 AEs included neutropenia (21.1%), and thrombocytopenia (15.8%). Conclusions: The combination of Tucidinostat and EC-T had an acceptable safety profile and encouraging clinical responses, offering a neoadjuvant treatment option for patients with early HR+/HER2- breast cancer. Further research is required to validate these findings. Clinical trial information: NCT05400993 ." @default.
- W4379328186 created "2023-06-05" @default.
- W4379328186 creator A5000135673 @default.
- W4379328186 creator A5018093835 @default.
- W4379328186 creator A5028462911 @default.
- W4379328186 creator A5030373380 @default.
- W4379328186 creator A5032092477 @default.
- W4379328186 creator A5040314090 @default.
- W4379328186 creator A5050972164 @default.
- W4379328186 creator A5052629282 @default.
- W4379328186 creator A5055551987 @default.
- W4379328186 creator A5056677123 @default.
- W4379328186 creator A5061708005 @default.
- W4379328186 creator A5064046304 @default.
- W4379328186 creator A5067909616 @default.
- W4379328186 creator A5068979528 @default.
- W4379328186 creator A5070293749 @default.
- W4379328186 creator A5074182099 @default.
- W4379328186 creator A5088470075 @default.
- W4379328186 creator A5091823297 @default.
- W4379328186 date "2023-06-01" @default.
- W4379328186 modified "2023-10-17" @default.
- W4379328186 title "Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer." @default.
- W4379328186 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e12617" @default.
- W4379328186 hasPublicationYear "2023" @default.
- W4379328186 type Work @default.
- W4379328186 citedByCount "0" @default.
- W4379328186 crossrefType "journal-article" @default.
- W4379328186 hasAuthorship W4379328186A5000135673 @default.
- W4379328186 hasAuthorship W4379328186A5018093835 @default.
- W4379328186 hasAuthorship W4379328186A5028462911 @default.
- W4379328186 hasAuthorship W4379328186A5030373380 @default.
- W4379328186 hasAuthorship W4379328186A5032092477 @default.
- W4379328186 hasAuthorship W4379328186A5040314090 @default.
- W4379328186 hasAuthorship W4379328186A5050972164 @default.
- W4379328186 hasAuthorship W4379328186A5052629282 @default.
- W4379328186 hasAuthorship W4379328186A5055551987 @default.
- W4379328186 hasAuthorship W4379328186A5056677123 @default.
- W4379328186 hasAuthorship W4379328186A5061708005 @default.
- W4379328186 hasAuthorship W4379328186A5064046304 @default.
- W4379328186 hasAuthorship W4379328186A5067909616 @default.
- W4379328186 hasAuthorship W4379328186A5068979528 @default.
- W4379328186 hasAuthorship W4379328186A5070293749 @default.
- W4379328186 hasAuthorship W4379328186A5074182099 @default.
- W4379328186 hasAuthorship W4379328186A5088470075 @default.
- W4379328186 hasAuthorship W4379328186A5091823297 @default.
- W4379328186 hasConcept C121608353 @default.
- W4379328186 hasConcept C126322002 @default.
- W4379328186 hasConcept C143998085 @default.
- W4379328186 hasConcept C203092338 @default.
- W4379328186 hasConcept C2775860665 @default.
- W4379328186 hasConcept C2776694085 @default.
- W4379328186 hasConcept C2776755627 @default.
- W4379328186 hasConcept C2777176818 @default.
- W4379328186 hasConcept C2778292576 @default.
- W4379328186 hasConcept C2779786085 @default.
- W4379328186 hasConcept C2780835546 @default.
- W4379328186 hasConcept C2781190966 @default.
- W4379328186 hasConcept C31760486 @default.
- W4379328186 hasConcept C530470458 @default.
- W4379328186 hasConcept C535046627 @default.
- W4379328186 hasConcept C71924100 @default.
- W4379328186 hasConcept C90924648 @default.
- W4379328186 hasConceptScore W4379328186C121608353 @default.
- W4379328186 hasConceptScore W4379328186C126322002 @default.
- W4379328186 hasConceptScore W4379328186C143998085 @default.
- W4379328186 hasConceptScore W4379328186C203092338 @default.
- W4379328186 hasConceptScore W4379328186C2775860665 @default.
- W4379328186 hasConceptScore W4379328186C2776694085 @default.
- W4379328186 hasConceptScore W4379328186C2776755627 @default.
- W4379328186 hasConceptScore W4379328186C2777176818 @default.
- W4379328186 hasConceptScore W4379328186C2778292576 @default.
- W4379328186 hasConceptScore W4379328186C2779786085 @default.
- W4379328186 hasConceptScore W4379328186C2780835546 @default.
- W4379328186 hasConceptScore W4379328186C2781190966 @default.
- W4379328186 hasConceptScore W4379328186C31760486 @default.
- W4379328186 hasConceptScore W4379328186C530470458 @default.
- W4379328186 hasConceptScore W4379328186C535046627 @default.
- W4379328186 hasConceptScore W4379328186C71924100 @default.
- W4379328186 hasConceptScore W4379328186C90924648 @default.
- W4379328186 hasIssue "16_suppl" @default.
- W4379328186 hasLocation W43793281861 @default.
- W4379328186 hasOpenAccess W4379328186 @default.
- W4379328186 hasPrimaryLocation W43793281861 @default.
- W4379328186 hasRelatedWork W1979057726 @default.
- W4379328186 hasRelatedWork W2026040915 @default.
- W4379328186 hasRelatedWork W2069548442 @default.
- W4379328186 hasRelatedWork W2328084067 @default.
- W4379328186 hasRelatedWork W2379981061 @default.
- W4379328186 hasRelatedWork W2397786201 @default.
- W4379328186 hasRelatedWork W2415742371 @default.
- W4379328186 hasRelatedWork W3118368214 @default.
- W4379328186 hasRelatedWork W4225868084 @default.
- W4379328186 hasRelatedWork W4206891336 @default.
- W4379328186 hasVolume "41" @default.
- W4379328186 isParatext "false" @default.
- W4379328186 isRetracted "false" @default.
- W4379328186 workType "article" @default.